{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:26:45Z","timestamp":1762432005167,"version":"3.37.3"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s12185-021-03134-6","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T13:02:59Z","timestamp":1616763779000},"page":"618-621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["MPL exon 10 mutations other than canonical MPL W515L\/K mutations identified by in-house MPL exon 10 direct sequencing in essential thrombocythemia"],"prefix":"10.1007","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3263-3270","authenticated-orcid":false,"given":"Yuka","family":"Sugimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiki","family":"Nagaharu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohshi","family":"Ohishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ikejiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaname","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigehisa","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Tawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"3134_CR1","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.","journal-title":"PLoS Med"},{"key":"3134_CR2","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472\u20136.","journal-title":"Blood"},{"key":"3134_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","volume":"112","author":"PA Beer","year":"2008","unstructured":"Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112:141\u20139.","journal-title":"Blood"},{"key":"3134_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ajh.24338","volume":"91","author":"YC Elala","year":"2016","unstructured":"Elala YC, Lasho TL, Gangat N, Finke C, Barraco D, Haider M, et al. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. Am J Hematol. 2016;91:503\u20136.","journal-title":"Am J Hematol"},{"key":"3134_CR5","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1182\/blood-2003-10-3471","volume":"103","author":"J Ding","year":"2004","unstructured":"Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103:4198\u2013200.","journal-title":"Blood"},{"key":"3134_CR6","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3324\/haematol.2009.005918","volume":"94","author":"K Liu","year":"2009","unstructured":"Liu K, Martini M, Rocca B, Amos CI, Teofili L, Giona F, et al. Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica. 2009;94:1368\u201374.","journal-title":"Haematologica"},{"key":"3134_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1182\/blood.2019002561","volume":"135","author":"JL Bridgford","year":"2020","unstructured":"Bridgford JL, Lee SM, Lee CMM, Guglielmelli P, Rumi E, Pietra D, et al. Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning. Blood. 2020;135:287\u201392.","journal-title":"Blood"},{"key":"3134_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41408-018-0159-3","volume":"8","author":"N Szuber","year":"2018","unstructured":"Szuber N, Hanson CA, Lasho TL, Finke C, Ketterling RP, Pardanani A, et al. MPL-mutated essential thrombocythemia: a morphologic reappraisal. Blood Cancer J. 2018;8:121.","journal-title":"Blood Cancer J"},{"key":"3134_CR9","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/ejh.13236","volume":"102","author":"Y Edahiro","year":"2019","unstructured":"Edahiro Y, Araki M, Inano T, Ito M, Morishita S, Misawa K, et al. Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan. Eur J Haematol. 2019;102:516\u201320.","journal-title":"Eur J Haematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03134-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03134-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03134-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T02:47:56Z","timestamp":1698115676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03134-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["3134"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03134-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"assertion":[{"value":"28 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y. Sugimoto has received honoraria from Novartis and is an accepted researcher from Shojunkai Takeuchi Hospital. Y. Sugimoto and I. Tawara received funding from Takara Bio. Y. Sugimoto, K. Nagaharu, K. Ohishi, I. Tawara, and N. Katayama have received research support from Astellas, Kyowa Kirin, and Ono. K. Ohishi has received funding from PharmaEssentia. N. Katayama has received honoraria from Novartis, Celgene, and Chugai. No other authors have any conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}